Differentiated thyroid cancers: A comprehensive review of novel targeted therapies

Expert Review of Anticancer Therapy

Volumn 12, Issue 3, 2012, Pages 345-357

  Kojic, Katarina L ^a   Kojic, Stefan L ^a   Wiseman, Sam M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

antiangiogenesis drugs; clinical trials; differentiated thyroid cancer; targeted therapy; tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BORTEZOMIB; CABOZANTINIB; CELECOXIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; LENVATINIB; MOTESANIB; PAZOPANIB; PLACEBO; PROTEASOME; RETINOIC ACID; ROMIDEPSIN; ROSIGLITAZONE; SELUMETINIB; SORAFENIB; SUNITINIB; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; VANDETANIB; VEMURAFENIB; VORINOSTAT; XL 281;

ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; ALOPECIA; ANAPLASTIC CARCINOMA; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BREAST CANCER; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COLORECTAL CANCER; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; DYSPNEA; ENDOMETRIUM CANCER; FATIGUE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOPIGMENTATION; HYPOTHYROIDISM; INCREASED APPETITE; INFECTION; KIDNEY CANCER; LEUKOPENIA; LUNG CANCER; LYMPHOCYTOPENIA; MAPK GENE; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MYELOMA; NAUSEA; NEUTROPENIA; NONHUMAN; ONCOGENE RAS; PNEUMONIA; POORLY DIFFERENTIATED THYROID CANCER; PROGRESSION FREE SURVIVAL; PROTEINURIA; PROTO ONCOGENE; RAF GENE; RASH; RECEPTOR GENE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; SYNCOPE; THROMBOCYTOPENIA; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; UNSPECIFIED SIDE EFFECT; VEGF GENE; VEGF RECEPTOR GENE; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; CARCINOMA; CELL DEDIFFERENTIATION; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE PROGRESSION; DISEASE RESISTANCE; GENES, RAS; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; TARGETED GENE REPAIR; THERAPIES, INVESTIGATIONAL; THYROID GLAND; THYROID NEOPLASMS;

EID: 84857851384     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.8     Document Type: Review

References (94)

1. Sherman SI. Thyroid carcinoma. Lancet 361(9356), 501-511 (2003).
2. DeLellis RA. Pathology and genetics of thyroid carcinoma. J. Surg. Oncol. 94(8), 662-669 (2006).
3. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N. Engl. J. Med. 338(5), 297-306 (1998).
4. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Database report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995 (see comments). Cancer 83(12), 2638-2648 (1998).
5. Kojic SL, Strugnell SS, Wiseman SM. Anaplastic thyroid cancer: A comprehensive review of novel therapy. Expert Rev. Anticancer Ther. 11(3), 387-402 (2011).
6. Wiseman SM, Griffith OL, Deen S et al. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch. Surg. 142(8), 717-727; discussion 727-729 (2007).
7. Bible KC, Suman VJ, Molina JR et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a Phase 2 consortium study. Lancet Oncol. 11(10), 962-972 (2010).
8. Pinchot SN. Multi-targeted approach in the treatment of thyroid cancer. Ther. Clin. Risk Manag. 4(5), 935-947 (2008).
9. Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16(2), 109-142 (2006).
10. Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91(8), 2892-2899 (2006).
11. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: A period analysis. Lancet 360(9340), 1131-1135 (2002).
12. Brenner H, Stegmaier C, Ziegler H. Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium. Ann. Oncol. 16(6), 981-986 (2005).
13. Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2011. Toronto, ON, USA (2011).
14. Kent WD, Hall SF, Isotalo PA et al. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ 177(11), 1357-1361 (2007).
15. Shaha A. Selective surgical management of well-differentiated thyroid cancer. Ann. NY Acad. Sci. 1138, 58-64 (2008).
16. Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin. Oncol. (R. Coll. Radiol.) 22(6), 464-468 (2010).
17. Fagin J, Mitsiades N. Molecular pathology of thyroid cancer: Diagnostic and clinical implications. Best Pract. Res. Clin. Endocrinol. Metab. 22(6), 955-969 (2008).
18. Fagin JA. How thyroid tumors start and why it matters: Kinase mutants as targets for solid cancer pharmacotherapy. J. Endocrinol. 183(2), 249-256 (2004).
19. Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J. Clin. Endocrinol. Metab. 94(5), 1493-1499 (2009).
20. Riesco-Eizaguirre G, Santisteban P. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr. Relat. Cancer 14(4), 957-977 (2007).
21. Sherman SI. Targeted therapies for thyroid tumors. Mod. Pathol. 24(Suppl. 2), S44-S52 (2011).
22. Kapiteijn E, Schneider TC, Morreau H et al. New treatment modalities in advanced thyroid cancer. Ann. Oncol. 23(1), 10-8 (2012).
23. O'Neill CJ, Oucharek J, Learoyd D, Sidhu SB. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 15(2), 146-156 (2010).
24. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6(4), 389-395 (2000).
25. Tuttle RM, Fleisher M, Francis GL, Robbins RJ. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J. Clin. Endocrinol. Metab. 87(4), 1737-1742 (2002).
26. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 438(7070), 967-974 (2005).
27. Klein M, Picard E, Vignaud JM et al. Vascular endothelial growth factor gene and protein: Strong expression in thyroiditis and thyroid carcinoma. J. Endocrinol. 161(1), 41-49 (1999).
28. Klein M, Vignaud JM, Hennequin V et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 86(2), 656-658 (2001).
29. Lennard CM, Patel A, Wilson J et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129(5), 552-558 (2001).
30. Kanamori A, Abe Y, Yajima Y, Manabe Y, Ito K. Epidermal growth factor receptors in plasma membranes of normal and diseased human thyroid glands. J. Clin. Endocrinol. Metab. 68(5), 899-903 (1989).
31. Akslen LA, Myking AO, Salvesen H, Varhaug JE. Prognostic impact of EGF-receptor in papillary thyroid carcinoma. Br. J. Cancer 68(4), 808-812 (1993).
32. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer 92(5), 1331-1346 (2001).
33. Xiong HQ, Rosenberg A, LoBuglio A et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter Phase II Trial. J. Clin. Oncol. 22(13), 2610-2616 (2004).
34. Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 24(17), 2659-2665 (2006).
35. Inoue A, Suzuki T, Fukuhara T et al. Prospective Phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J. Clin. Oncol. 24(21), 3340-3346 (2006).
36. Ball DW. Medullary thyroid cancer: Therapeutic targets and molecular markers. Curr. Opin. Oncol. 19(1), 18-23 (2007).
37. Laird AD, Cherrington JM. Small molecule tyrosine kinase inhibitors: Clinical development of anticancer agents. Expert Opin. Investig. Drugs 12(1), 51-64 (2003).
38. Wiseman SM, Masoudi H, Niblock P et al. Anaplastic thyroid carcinoma: Expression profile of targets for therapy offers new insights for disease treatment. Ann. Surg. Oncol. 14(2), 719-729 (2007).
39. Nikiforov YE. Thyroid carcinoma: Molecular pathways and therapeutic targets. Mod. Pathol. 21, S37-S43 (2008).
40. Ishii Y, Waxman S, Germain D. Targeting the ubiquitin-proteasome pathway in cancer therapy. Anticancer Agents Med. Chem. 7(3), 359-365 (2007).
41. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 5(7), 419-429 (2004).
42. Chougnet C, Brassard M, Leboulleux S, Baudin E, Schlumberger M. Molecular targeted therapies for patients with refractory thyroid cancer. Clin. Oncol. (R. Coll. Radiol.) 22(6), 448-455 (2010).
43. Xing M. BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 28(7), 742-762 (2007).
44. Knauf JA, Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr. Opin. Cell Biol. 21(2), 296-303 (2009).
45. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363(9), 809-819 (2010).
46. Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol. 26(29), 4714-4719 (2008).
47. Ahmed M, Barbachano Y, Riddell A et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: A Phase II study in a UK based population. Eur. J. Endocrinol. 165(2), 315-322 (2011).
48. Hoftijzer H, Heemstra KA, Morreau H et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 161(6), 923-931 (2009).
49. Hong DS, Cabanillas ME, Wheler J et al. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J. Clin. Endocrinol. Metab. 96(4), 997-1005 (2011).
50. Hong DS, Sebti SM, Newman RA et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin. Cancer Res. 15(22), 7061-7068 (2009).
51. Kloos RT, Ringel MD, Knopp MV et al. Phase II trial of sorafenib in metastatic thyroid cancer. J. Clin. Oncol. 27(10), 1675-1684 (2009).
52. Leboeuf R, Baumgartner JE, Benezra M et al. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J. Clin. Endocrinol. Metab. 93(6), 2194-2201 (2008).
53. Lucas AS, Cohen EE, Cohen RB et al. Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements. J. Clin. Oncol. 28(Suppl.), 15s (2010) (Abstract 5536).
54. Schwartz GK, Robertson S, Shen A et al. A Phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. ASCO Meeting Abstracts 27(15S), 3513 (2009).
55. Cabanillas ME, Waguespack SG, Bronstein Y et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: The M. D. Anderson experience. J. Clin. Endocrinol. Metab. 95(6), 2588-2595 (2010).
56. Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: A new paradigm for combination therapy. Nat. Med. 7(9), 987-989 (2001).
57. O'Neill JP, Power D, Condron C, Bouchier-Hayes D, Walsh M. Anaplastic thyroid cancer, tumorigenesis and therapy. Ir. J. Med. Sci. 179(1), 9-15 (2009).
58. Antonelli A, Fallahi P, Ferrari SM et al. Dedifferentiated thyroid cancer: A therapeutic challenge. Biomed. Pharmacother. 62(8), 559-563 (2008).
59. Sun L, Liang C, Shirazian S et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 46(7), 1116-1119 (2003).
60. Puxeddu E, Romagnoli S, Dottorini ME. Targeted therapies for advanced thyroid cancer. Curr. Opin. Oncol. 23(1), 13-21 (2011).
61. Cohen EE, Needles BM, Cullen KJ et al. Phase 2 study of sunitinib in refractory thyroid cancer. ASCO Meeting Abstracts 26(Suppl. 15), 6025 (2008).
62. Carr L, Goulart B, Martins R et al. Phase II trial of continuous dosing of sunitinib in advanced, FDG-PET avid, medullary thyroid carcinoma (MTC) and well-differentiated thyroid cancer (WDTC). ASCO Meeting Abstracts 27(15S), 6056 (2009).
63. Carr LL, Mankoff DA, Goulart BH et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin. Cancer Res. 16(21), 5260-5268 (2010).
64. Ravaud A, de la Fouchardiere C, Courbon F et al. Sunitinib in patients with refractory advanced thyroid cancer: The THYSU Phase II trial. ASCO Meeting Abstracts 26(Suppl. 15), 6058 (2008).
65. Rosen LS, Kurzrock R, Mulay M et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 25(17), 2369-2376 (2007).
66. Sherman SI, Wirth LJ, Droz JP et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N. Engl. J. Med. 359(1), 31-42 (2008).
67. Bass MB, Sherman SI, Schlumberger MJ et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J. Clin. Endocrinol. Metab. 95(11), 5018-5027 (2010).
68. Commander H, Whiteside G, Perry C. Vandetanib: First global approval. Drugs 71(10), 1355-1365 (2011).
69. Leboulleux S, Bastholt L, Krause TM et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer (papillary or follicular; DTC): A randomized, double-blind Phase II trial Ann. Oncol. 21, 315 (2010) (Abstract).
70. Cohen EEW, Rosen LS, Vokes EE et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a Phase II study. J. Clin. Oncol. 26(29), 4708-4713 (2008).
71. Fuente N, Mane JM, Barcelo R et al. Tumor lysis syndrome in a multiple myeloma treated with thalidomide. Ann. Oncol. 15(3), 537 (2004).
72. Ain KB, Lee C, Williams KD. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 17(7), 663-670 (2007).
73. Mrozek E, Kloos RT, Ringel MD et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 91(6), 2201-2204 (2006).
74. Sherman SI, Jarzab B, Cabanillas ME et al. A Phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 5503).
75. Cabanillas M, Brose MS, Ramies DA et al. Anti-tumor activity observed in a cohort of patients with differentiated thyroid cancer (DTC) in a Phase I study of cabozantinib (XL184). Thyroid 21(S1), (2011) (Abstract A-1-A-110).
76. Pennell NA, Daniels GH, Haddad RI et al. A Phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18(3), 317-323 (2008).
77. Stenner F, Liewen H, Zweifel M et al. Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. Cancer Sci. 99, 1847-1852 (2008).
78. Yang Y, Kitagaki J, Wang H, Hou DX, Perantoni AO. Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci. 100(1), 24-28 (2009).
79. Harvey RD, Kauh JS, Ramalingam SS et al. Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer. J. Clin. Oncol. 28(Suppl.), 15s (2010) (Abstract 5589).
80. Jeong H, Kim YR, Kim KN et al. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl. Med. Biol. 33(7), 875-882 (2006).
81. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov. 6(10), 793-810 (2007).
82. Gruning T, Tiepolt C, Zophel K et al. Retinoic acid for redifferentiation of thyroid cancer - does it hold its promise? Eur. J. Endocrinol. 148(4), 395-402 (2003).
83. Short SC, Suovuori A, Cook G, Vivian G, Harmer C. A Phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin. Oncol. (R. Coll. Radiol.) 16(8), 569-574 (2004).
84. Mitsiades CS, Poulaki V, McMullan C et al. Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin. Cancer Res. 11(10), 3958-3965 (2005).
85. Woyach JA, Kloos RT, Ringel MD et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J. Clin. Endocrinol. Metab. 94(1), 164-170 (2009).
86. Furuya F, Shimura H, Suzuki H et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 145(6), 2865-2875 (2004).
87. Sherman EJ, Fury MG, Tuttle RM et al. Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma. J. Clin. Oncol. 27(Suppl.), 15s (2009) (Abstract 6059).
88. Su Y, Tuttle R, Fury M et al. A Phase II study of single agent depsipeptide (DEP) in patients (pts) with radioactive iodine (RAI)-refractory, metastatic, thyroid carcinoma: Preliminary toxicity and efficacy experience. J. Clin. Oncol. 24(Suppl.) (2006) (Abstract 5554).
89. Piekarz R, Luchenko V, Draper D et al. Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 3571).
90. Philips JC, Petite C, Willi JP, Buchegger F, Meier CA. Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers. Nucl. Med. Commun. 25(12), 1183-1186 (2004).
91. Kebebew E, Lindsay S, Clark OH et al. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid 19(9), 953-956 (2009).
92. Woyach JA, Shah MH. New therapeutic advances in the management of progressive thyroid cancer. Endocr. Relat. Cancer 16(3), 715-731 (2009).
93. Sherman SI. Targeted therapy of thyroid cancer. Biochem. Pharmacol. 80(5), 592-601 (2010).
94. Holt RA, Jones SJ. The new paradigm of flow cell sequencing. Genome Res. 18(6), 839-846 (2008).